Program
Diphenhydramine
Also written as “Ibuprofen and Diphenhydramine Citrate”, “Diphenydramine” and “Diphenhydramine Hydrochloride Injection”.
Its studies are mostly in Sleep Initiation and Maintenance Disorders · Nasal Obstruction · Multiple Sclerosis · Depressive Disorder, Major · Urticaria, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 40 open or running | phase 4since Mar 20, 2008 | Mar 20, 2008 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Jan 20, 2010 | Jan 20, 2010 | none ahead |
| lumara-health-inc | 10 open or running | phase 2since Dec 26, 2007 | Dec 26, 2007 | none ahead |
| Lunan Pharmaceutical Group | 11 open or running | phase 3since Feb 6, 2025 | Feb 6, 2025 | none ahead |
| Otsuka | 10 open or running | phase 1since Nov 25, 2012 | Nov 25, 2012 | none ahead |
| Overseas Pharmaceuticals | 10 open or running | phase 1since Feb 6, 2023 | Feb 6, 2023 | none ahead |
| Pfizer | 10 open or running | phase 1since May 5, 2010 | May 5, 2010 | none ahead |
| Procter and Gamble | 10 open or running | phase 4since Oct 14, 2015 | Oct 14, 2015 | none ahead |
| TerSera Therapeutics | 10 open or running | phase 2since Dec 3, 2019 | Dec 3, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 26, 2007First study: phase 2 study in VulvodyniaNew to lumara-health-inclumara-health-inc · NCT00590590 · 105 enrolled · United States, Canada
- Mar 20, 2008Johnson & Johnson's first study: phase 1 study in Nasal ObstructionNew to Johnson & JohnsonJohnson & Johnson · NCT00662337 · 36 enrolled
- Mar 20, 2008Phase 4 study in Nasal ObstructionJohnson & Johnson · NCT00648973 · 1,021 enrolled · United States
- Sep 26, 2008Phase 1 study in Rhinitis, AllergicJohnson & Johnson · NCT00762749 · 36 enrolled · United States
- Jan 20, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01053338, NCT01053208
- May 5, 2010Pfizer's first study: phase 1 study in HealthyNew to PfizerPfizer · NCT01119222 · 19 enrolled · Belgium
- Nov 25, 2012Otsuka's first study: phase 1 study in HealthyNew to OtsukaOtsuka · NCT01737931 · 120 enrolled · Korea, Republic of
- May 29, 2015Phase 1 study in Depressive Disorder, MajorJohnson & Johnson · NCT02476058 · 48 enrolled · Belgium, Germany, Netherlands
- Oct 14, 2015Procter and Gamble's first study: phase 4 study in Occasional SleeplessnessNew to Procter and GambleProcter and Gamble · NCT02578186 · 33 enrolled
- Dec 3, 2019TerSera Therapeutics's first study: phase 2 study in Oncology Patients Receiving ChemotherapyNew to TerSera TherapeuticsTerSera Therapeutics · NCT04189588 · 34 enrolled · United States
- Feb 6, 2023Overseas Pharmaceuticals's first study: phase 1 study in PainNew to Overseas PharmaceuticalsOverseas Pharmaceuticals · NCT05729555 · 16 enrolled · China
- Feb 6, 2025Lunan Pharmaceutical Group's first study: phase 3 study in Acute UrticariaNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06819774 · 284 planned · China
TargetBeta
“Histamine H1 receptor antagonist; Histamine H1 receptor antagonist”ChEMBL 37, by rule
Other programs on HRH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| desloratadinerule | Organon | phase 4 | 40 |
| fexofenadinerule | Sanofi | phase 4 | 38 |
| bilastinerule | faes-farma-s-a | phase 4 | 19 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06819774Acute Urticaria · China | 3 | Recruiting | Lunan Pharmaceutical Group | Aug 2025 | 284 |
| NCT05729555Pain · China | 1 | UNKNOWN | Overseas Pharmaceuticals | Oct 31, 2023 | 16 |
| NCT04189588Oncology Patients Receiving Chemotherapy · United States | 2 | Completed | TerSera Therapeutics | Nov 23, 2020 | 34 |
| NCT02578186Occasional Sleeplessness | 4 | Completed | Procter and Gamble | Dec 2014 | 33 |
| NCT02476058Depressive Disorder, Major · Belgium, Germany, Netherlands | 1 | Completed | Johnson & Johnson | Jan 4, 2016 | 48 |
| NCT01737931Healthy · Korea, Republic of | 1 | Completed | Otsuka | Oct 2012 | 120 |
| NCT01119222Healthy · Belgium | 1 | Completed | Pfizer | Oct 2008 | 19 |
| NCT01053338Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Apr 2008 | 40 |
| NCT01053208Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Apr 2008 | 40 |
| NCT00762749Rhinitis, Allergic · United States | 1 | Completed | Johnson & Johnson | Nov 2008 | 36 |
| NCT00662337Nasal Obstruction | 1 | Completed | Johnson & Johnson | Nov 2006 | 36 |
| NCT00648973Nasal Obstruction · United States | 4 | Completed | Johnson & Johnson | May 2007 | 1,021 |
| NCT00590590Vulvodynia · United States, Canada | 2 | Completed | lumara-health-inc | Jun 2009 | 105 |
How it is read
Names in the registry
- “Diphenhydramine”, 2 entries
- “Ibuprofen and Diphenhydramine Citrate”, 2 entries
- “Diphenydramine”, 1 entry
- “Diphenhydramine Hydrochloride Injection”, 1 entry
- “Diphenhydramine 50 mg/mL”, 1 entry
Conditions, from the studies’ own filings
- Sleep Initiation and Maintenance Disorders, 2 studies
- Nasal Obstruction, 2 studies
- Multiple Sclerosis, 1 study
- Depressive Disorder, Major, 1 study
- Urticaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.